An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease

An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease - An open-labeled single arm study on improvement of cognitive function by istradefylline for parkinson disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037422

Enrollment

Registered

2019-08-01

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson disease

Interventions

Prescription istradefylline 20 mg for 1 month, and if there are no side effects, increase to 40 mg and prescribe for 2 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients meet clinically established or clinically probable cases of clinical diagnostic criteria of Parkinson disease by Movement Disorder Society 2. The item of Attention/memory in NMSS is 1 or more. 3. The patient is treated with drugs that include L-dopa 4. The age of patients is 40 to 85years old. 5. Written consent has been obtained

Exclusion criteria

Exclusion criteria: 1. Istradefylline has been prescribed. 2. The patient can not stand. 3. The angle of camptocormia is less than 10 degrees.

Design outcomes

Primary

Measure	Time frame
Primary outcome is the angle of camptocormia	—

Secondary

Measure	Time frame
Secondary outcomes are Movement Disorder Society-Unified Parkinson Disease Rating Scale(MDS-UPDRS), Non-motor symptoms scales.	—

Countries

Japan

Contacts

Public ContactMasahiro Kanai

Ichinomiya Nishi Hospital Neurology

masabilliard35@yahoo.co.jp0586480077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026